These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34353757)

  • 1. Trimodality Versus Bimodality Therapy in Patients With Locally Advanced Esophageal Carcinoma: Commentary on the American Society of Clinical Oncology Practice Guidelines.
    Vitzthum LK; Hui C; Pollom EL; Chang DT
    Pract Radiat Oncol; 2021; 11(6):429-433. PubMed ID: 34353757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Jeong Y; Kim JH; Kim SB; Yoon DH; Park SI; Kim YH; Kim HR; Jung HY; Lee GH; Ryu JS
    J Surg Oncol; 2014 Apr; 109(5):472-7. PubMed ID: 24301552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian post-hoc analysis of chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.
    Zhou N; Lee KH; Pedroza C; Hofstetter WL
    J Thorac Cardiovasc Surg; 2022 Sep; 164(3):688-693.e1. PubMed ID: 34933771
    [No Abstract]   [Full Text] [Related]  

  • 4. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.
    Barbetta A; Hsu M; Tan KS; Stefanova D; Herman K; Adusumilli PS; Bains MS; Bott MJ; Isbell JM; Janjigian YY; Ku GY; Park BJ; Wu AJ; Jones DR; Molena D
    J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2710-2721.e3. PubMed ID: 29548582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy or chemoradiotherapy for locally advanced esophageal cancer.
    Smithers BM; Thomson I
    Thorac Surg Clin; 2013 Nov; 23(4):509-23. PubMed ID: 24199701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
    Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
    Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
    Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
    Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer.
    Wongwaiyut K; Ruangsin S; Laohawiriyakamol S; Leelakiatpaiboon S; Sangthawan D; Sunpaweravong P; Sunpaweravong S
    J Gastrointest Cancer; 2020 Sep; 51(3):947-951. PubMed ID: 31758468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
    Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
    Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.
    Lin WC; Ding YF; Hsu HL; Chang JH; Yuan KS; Wu ATH; Chow JM; Chang CL; Chen SU; Wu SY
    Cancer; 2017 Oct; 123(20):3904-3915. PubMed ID: 28608916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience.
    Sio TT; Wilson ZC; Stauder MC; Bhatia S; Martenson JA; Quevedo JF; Schomas DA; Miller RC
    Am J Clin Oncol; 2016 Oct; 39(5):448-52. PubMed ID: 24879469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma.
    Chen WH; Chao YK; Chang HK; Tseng CK; Wu YC; Liu YH; Hsieh MJ; Liu HP
    Dis Esophagus; 2012 Apr; 25(3):250-5. PubMed ID: 21951719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Ibuki Y; Yamakita I; Kurokawa T; Nagata Y; Okada M
    World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress in multidisciplinary treatment for patients with esophageal cancer.
    Watanabe M; Otake R; Kozuki R; Toihata T; Takahashi K; Okamura A; Imamura Y
    Surg Today; 2020 Jan; 50(1):12-20. PubMed ID: 31535225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma.
    Guo JC; Huang TC; Lin CC; Hsieh MS; Chang CH; Huang PM; Lee JM; Hsu FM; Chia-Hsien Cheng J; Wang HP; Yeh KH; Cheng AL; Hsu CH
    J Thorac Oncol; 2015 Oct; 10(10):1481-9. PubMed ID: 26313683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study.
    van der Woude SO; Hulshof MC; van Laarhoven HW
    Chin Clin Oncol; 2016 Feb; 5(1):13. PubMed ID: 26932437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimodality Approach for Esophageal Malignancies.
    Watkins AA; Zerillo JA; Kent MS
    Surg Clin North Am; 2021 Jun; 101(3):453-465. PubMed ID: 34048765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
    Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
    J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.